The regulation of p53 by phosphorylation: a model for how distinct










































The Biochemistry and Genetics of p53 Function 
 
p53 is a sequence-specific DNA-binding protein and 
stress-activated transcription factor that controls the 
expression of hundreds of genes implicated in a variety 
of physiological responses to genome instability, virus 
infection and interferon production, DNA damage, 
metabolic stresses such as hypoxia, and cytokine 
signaling. The vast numbers of gene products mediating 
the p53 signal coordinately promote many repair pro-
cesses, some of which include elimination of damaged 
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proteins, DNA repair, ATP generation via oxidative 
phosphorylation, organellar functions that maintain 
autophagy signaling and mitochondrial function, the 
cell division cycle, and programmed cell death. The 
implications of this stress-induced transcription re-
programming by p53 is that cell and tissue integrity can 
be maintained, thereby contributing to organism health 
and viability. 
 
Inactivating missense mutations in p53  are very 
common in a wide range of human cancers, indicating a 
critical role for p53 as a cancer suppressor in very 
distinct tissue microenvironments [1]. These missense 
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binding domain or tetramerisation domain (Figure 1), 
and result in a p53 protein with an altered conformation 
and attenuated sequence-specific DNA-binding function 
[2]. These mutations thus suppress p53 transcription, 
reduce the cellular repair capacity, and stimulate 
tumourigenesis. As p53 is a conformationally flexible 
and thermodynamically unstable protein, biophysical 
studies have suggested there might be promise in drug 
developments aimed at stabilizing the mutant p53 
conformation into a wild-type state, and re-engaging the 
p53 transcription program [3]. 
 
Transgenic technologies in mice have supported 
biochemical and clinical data showing a critical role for 
the DNA-binding function of p53 in cancer suppression. 
Animals null for p53  strikingly develop cancer at an 
advanced rate [4]. By contrast, deletion of many of the 
p53-inducible genes do not give the same tumour 
incidence or tumour spectrum as p53-null animals [5], 
further highlighting the role of p53 itself as a central 
hub in the integration of tissue repair triggers. There is 
one intriguing exception: animals double null for ataxia 
telangiectasia mutated (ATM) and the p53-inducible 
gene  p21  have a similar tumour spectrum and death 
incidence to the p53-null animals [6]. This suggests that 
ATM and p21 form a positive genetic circuit in the p53-



























In addition to a role for p53 in cancer control, transgenic 
studies have also indicated that p53 can play a role in 
aging-related processes that are triggered by telomere 
erosion or oxidative damage to proteins, lipids or DNA, 
which in turn affect phenotypes including neuromuscular 
coordination and longevity. The first such transgenic p53 
animal exhibited a genetic alteration that resulted in the 
constitutive production of a C-terminal fragment of p53 
that escaped degradation from its key negative regulator, 
the E3 ubiquitin ligase MDM2. These animals exhibited 
aging phenotypes including reduced longevity, osteo-
porosis, generalized organ atrophy and a diminished 
stress tolerance [7]. A second transgenic study showing 
that enhanced p53 function promotes aging utilized 
another truncated form of p53 with mutations in the 
MDM2-binding domain [8]. An additional transgenic 
model displaying a pro-aging phenotype had a BRCA1 
mutation that constitutively activates p53 via the 
enhanced endogenous DNA damage signals [9]. There is 
also some biochemical and clinical data suggesting that 
p53 activation might play a role in human diseases of 
aging. Recent reports have shown that p53 activation can 
trigger the pathways that promote tau protein aggrega-
tion, which in turn is thought to reflect specific stages in 
Alzheimer’s disease [10]. Further, the activation of p53 
by  β-amyloid peptides might prove in vivo to either 
suppress the accumulation of abnormal neurons by 
apoptotic pathways, or induce cell loss resulting in 




























human  p53  showing  the  sites  of  post‐translational  modification  including  phosphorylation,  acetylation,  ubiquitination,  methylation,
neddylation,  and  sumoylation.  Abbreviations:  N‐terminal  transactivation  domain  (TAD);  proline‐rich  domain  (PRD);  tetramerisation
domain (TET); C‐terminal regulatory domain (REG); arginine (R); lysine (K); serine (S); threonine (T). 
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concept that elevated p53 activation might promote 
aging, which in turn seems to fit well with the models 
that the evolution of p53 might have come about as a 
trade-off between pathways that regulate longevity and 
maintain tissue integrity. Too much p53 might promote 
more efficient cancer suppression at the cost of elevated 
aging; whilst increasing longevity through reduced p53 
function might result in elevated cancer development. 
However, other genetic studies that alter p53 levels 
have not supported these interpretations. Transgenic 
mice with either elevated p53  gene dosage [12] or 
hypomorphic MDM2 function [13] have no effect on 
the aging phenotype, although the animals have reduced 
cancer incidence, which would be expected if p53 
function was in fact elevated. 
 
These two distinct outcomes have been interpreted to 
indicate that when the p53  gene is under its normal 




































engaged [14]. On the other hand, artificial activation of 
p53 results in the abnormal production of a pro-aging 
phenotype, suggesting that p53 promotes aging only 
under abnormal or pathological circumstances [14]. This 
discrepancy has been resolved in part by the most recent 
study in which animals with enhanced p19
ARF and p53 
were generated that are under normal physiological 
control. These doubly transgenic mice displayed en-
hanced resistance to cancer and reduced aging characte-
ristics, including increased longevity [15], thus identi-
fying a previously unknown anti-aging signaling trigger 
in vertebrates. Two key p53-inducible gene products that 
could play a role in this p53 anti-aging program are the 
antioxidants Sestrins1 and 2 whose induction by the 
ARF-activation signal presumably attenuates the 
accumulation of reactive oxygen species and associated 
damaged cellular constituents that would normally 
promote aging [16]. Thus, an understanding of the 
physiological factors that regulate the specific activity of 









































between  urochordate  and  human.  The  panel  highlights  the  conservation  of  amino  acids  and  phospho‐acceptor  sites  in  the  BOX‐I
transactivation domain of p53 (TAD1 in Figure 2A) between human and urochordate (Ciona intestinalis). The ATM phospho‐acceptor site
at Ser15 and the Calcium Calmodulin kinase/CK1 phospho‐acceptors sites at Thr18 and Ser20 are highlighted as indicated. 
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p53 protein function is regulated post-translationally by 
co-ordinated interaction with signaling proteins 
including protein kinases, acetyltransferases, methyl-
transferses, and ubiquitin-like modifying enzymes 
(Figure 1). The majority of the sites of covalent 
modification occur at intrinsically unstructured linear 
peptide docking motifs that flank the DNA-binding 
domain of p53 which play a role in anchoring or in 
allosterically activating the enzymes that mediate 
covalent modification of p53 (Figure 2A). Such 
unstructured linear domains are proving to be important 
in signaling control [17-19]. In undamaged cells, p53 
protein has a relatively short half-life and is degraded 
by a ubiquitin-proteasome dependent pathway through 
the action of E3 ubiquitin ligases including MDM2, 
PirH2, COP-1, and CHIP [20]. Following stress, p53 is 
phosphorylated at multiple residues, thereby modifying 
its biochemical functions required for increased activity 
as a transcription factor. The biochemical functions 
include sequence-specific DNA binding and protein-
protein interactions. Acetylation of p53 is DNA-
dependent, and this modification facilitates chromatin 
remodeling and activation of p53 target gene expression 
[21, 22]. Of the dozens of phospho-acceptor sites 
reported on p53 only three (Ser15, Thr18, Ser20) are 
highly conserved between humans and urochordates 
(Figure 2B), the latter being where a bona-fide p53-
MDM2 axis has appeared in evolution. Especially 
striking is the conservation of primary amino acid 
homology in the p53 transactivation domain between 
the invertebrate sea squirt and humans, indicating that 
as yet undefined evolutionary selection pressures have 
maintained this amino acid sequence at least since this 
urochordate lineage. The only other highly conserved 
phosphorylation site in p53 is within the C-terminus of 
p53 and is conserved only amongst vertebrates; the CK2 
site at Ser392. As such, we have focused our research 
on studying two of these highly conserved phosphory-
lation sites in p53: the Ser20 site and the Ser392 site, as 
they form a paradigm to facilitate our understanding of 
how phosphorylation controls p53 function as a 
transcription factor. The many other sites of covalent 
modification on p53 (Figure 1) also likely play 
important roles in p53 function or regulation, but there 
are relatively smaller amounts of genetic and 
biochemical data describing the effects of these 
modifications on p53 function. 
 
The Ser392 phospho-acceptor site is located in the C-
terminal regulatory domain (REG) in a flexible and 
unstructured motif (Figures 1 and 2) whose phosphory-
lation by casein kinase 2 (CK2) stimulates the 
sequence-specific DNA-binding function of p53 [23]. 
This activation of p53 presumably occurs by changes in 
the conformation of the DNA binding domain that 
increases p53 thermostability as defined with 
biophysical studies using a phospho-mimetic S392D 
mutant p53 protein [24]. This Ser392 site is flanked by 
a sumoylation site [25] and a cyclin A-docking site [26]. 
Phosphorylation at p53 Ser392 also increases after 
either UV or ionizing radiation in cell lines, in mice 
spleenocytes  in vivo, and in human skin basal cell 
populations [27-29]. These data are consistent with an 
activating rather than inhibitory role for phospho-
rylation of this site on p53 function. Critically, 
substitution mutation of the murine equivalent of 
Ser392 to Ala392 results in enhanced UV-induced skin 
cancer and elevated carcinogen-induced bladder cancer 
in transgenic mice [30, 31]. These data identify a p53-
activating kinase pathway whose attenuation could 
modify aging-related diseases in squamous tissue like 
skin and bladder. Whether phosphorylation of p53 at the 
Ser392 site plays a tumour suppressing role in other 
cancer types remains to be determined. 
 
The second highly conserved phospho-acceptor site, 
Ser20, is located in the N-terminal transactivation 
domain (TAD) in an unstructured linear motif (Figures 
1 and 2) whose phosphorylation stabilizes the binding 
of the transcriptional co-activator p300 by creating a 
phospho-SDLxxLL docking motif [21, 22, 32]. The 
docking of p300 to this motif is required to promote 
DNA-dependent acetylation of p53 at promoters, and 
hence transcriptional activation of p53 target genes. 
Mutation of Ser20 to Asp20, thereby mimicking 
constitutive phosphorylation of p53 Ser20, results in a 
p53 with enhanced transcription function in cell lines 
[33, 34]. Further, as Ser20 site phosphorylation is 
elevated after DNA damage [35, 36], these data suggest 
that phosphorylation at p53 Ser20 forms a stimulatory 
rather than an inhibitory signal for p53 activity. 
Transgenic mice with a phospho-acceptor site mutation 
at the Ser20 equivalent in murine p53 have been shown 
to develop spontaneous B-cell lymphoma [37], 
providing evidence of the first spontaneous cancer-
prone phenotype for a p53 covalent regulatory site. 
Further, as B-cells from these transgenic mice exhibit 
attenuated ionizing radiation-induced apoptosis in vitro 
[37], these data highlight a central role for Ser20 site 
phosphorylation in p53-dependent apoptotic activation 
in this cell type. 
 
Together, these biochemical and genetic studies show 
that phosphorylation can activate p53 function, although 
these studies do not necessarily explain what selection 
pressures have maintained the integrity of the Ser20 and 
Ser392 phospho-acceptor sites during evolution in the 
urochordate-chordate lineage. Nevertheless, the apparent 
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translational modification signaling pathways highlights 
the need to develop tissue-specific experimental cancer 
models that reflect the physiological switches that can 
activate p53, including changes in cytokoines like 
transforming growth factor β (TGF-β) or interferons, 
metabolic stresses like hypoxia, glucose starvation or 
acidification, external stresses including carcinogen 
damage to DNA, and internal signals such as oncogene 
activation. 
 
The Enzymatic Pathways that Regulate p53 
Phosphorylation at Ser20 
 
Although one of the key paradigms in the p53 field is 
that p53 integrates diverse microenvironmental stresses 
into an outcome (Figure 3), the molecular mechanisms 
whereby these stresses activate p53 are only beginning 
to be defined. DNA damage activation has been the 
most widely studied signal input into p53. The 
checkpoint kinases 1 and/or 2 (CHK1/2) have been 


































site kinase(s) [38]. These enzymes have evolved an 
allosteric docking site in the DNA-binding domain of 
p53 (Figure 2A) that induces phosphorylation of p53 at 
Ser20 [39, 40], and a second interaction site for CHK2 
was identified in the proline-rich domain (PRD) of p53 
[41]. Studies in transgenic mice have shown that CHK2 
is required to mediate the p53-dependent response to 
ionizing radiation [42]. Although these data indicate 
CHK2 is the most likely Ser20 site kinase for p53, 
genetic screens have not supported this conclusion. The 
use of siRNA to CHK1 or CHK2 does not abrogate the 
damage-induced stabilization of p53 [43], and the 
knockout of CHK2 in cancer cell lines does not 
compromise Ser20 site phosphorylation [44]. Thus, the 
ionizing radiation-induced kinase that targets the Ser20 
site of p53 is still undefined. In this study, we set out to 
identify the p53 Ser20 kinase(s) induced by three very 
different stresses that are known to activate p53: 
ionizing radiation, viral infection, and metabolic stress 
to determine whether the p53 “integration” of distinct 
stress signals to this phospho-acceptor site goes through 







































   














































































































   
www.impactaging.com                  495                                       AGING, May    2009, Vol.1 No.5RESULTS 
 
In attempts to define whether the activation of p53 
Ser20 site kinase(s) induced by different stresses is 
triggered by the same or different signaling pathways, 
we treated cells with specific kinase inhibitors in 
combination with distinct stresses known to activate 
p53. We performed all experiments using one cell 
culture model, namely the MOLT-3 cell line, which is a 
human acute lymphoblastic leukaemia T-cell line. The 
MOLT-3 cell line was first validated using ionizing 
radiation and kinase inhibitors specific for CHK2, 
CHK1 and ATM. As a control consistent with siRNA 
screens for CHK2 [43], the X-ray-induced Ser20 site 
phosphorylation of p53 was not attenuated by the CHK2 
inhibitor (Figure 4A and B; lanes 6, 8, 10, 12 vs 5, 7, 9, 
11). Further, the CHK1 inhibitor SB218078 was equally 
unable to prevent Ser20 site phosphorylation induced by 
X-rays (Figure 4C and D; lanes 6, 8, 10, 12 vs 5, 7, 9, 
11). In fact, X-ray induced phosphorylation at Ser20 
was elevated (Figure 4 C and D; lanes 6, 8, 10, 12 vs 4), 
and basal levels of p53 were stabilized by the CHK1 
inhibitor in the absence X-ray treatment (Figure 4C and 
D; lanes 5, 7, 9, 11 vs 3). However, this stabilized form 
of p53 in undamaged cells was not phosphorylated at 
Ser20 (Figure 4C & D; lanes 5, 7, 9, 11). 
 
These data are consistent with the recent study showing 
that CHK1 loss can activate p53 [45] and that CHK2 
loss does not prevent Ser20 site phosphorylation [43]. 
Nevertheless, the treatment of cells with the specific 
ATM inhibitor KU-55933 resulted in a dose-dependent 
attenuation of X-ray-induced Ser20 site phosphorylation 
(Figure 4E; lanes 6, 8, 10, 12 vs 4). These data indicate 
that the X-ray-induced phosphorylation of p53 at Ser20 
is ATM-dependent (Figure 3), but since ATM 
consensus sites require an SQ core motif, it is not 
possible for ATM to be the direct Ser20 site kinase. 
 
Because the X-ray induced Ser20 kinase was still 
undefined, we examined whether other kinase signalling 
pathways, including casein kinase 1 (CK1), were 
involved. CK1 was identified as the human herpesvirus 
6B (HHV-6B)-induced protein kinase that targets the 
Ser20 site on p53 [46]. Other DNA and RNA viruses 
are also able to activate p53 function, consistent with 
the intrinsic interferon-α/β responsiveness of the p53 
pathway [47]. Whether these other viruses also induce 
p53 phosphorylation at Ser20 is not fully defined. As 
reported previously [46], the treatment of HHV-6B 
infected cells with the specific CK1 inhibitor D4476 
resulted in a dose-dependent attenuation of Ser20 site 
phosphorylation (Figure 5A; lanes 4, 6, 8, 10, 12, 14 vs 
2). However, the CK1 inhibitor had no effect on the X-
ray-induced p53 Ser20 phosphorylation (Figure 5B; 
lanes 6, 8, 10, 12 vs 5, 7, 9, 11). Together, these data 
indicate that Ser20 site phosphorylation is ATM-depen-
dent after ionizing irradiation, but CK1-dependent after 
























































for  48  hours  in  the  presence  of  increasing  concentrations  (10‐
100μM) of the CK1 inhibitor D4476 (lanes 3‐14) or a DMSO solvent
control  (lanes  1‐2).  Cell  lysates  were  examined  by  Western
blotting with antibodies against the indicated proteins. (B) A CK1
inhibitor does not attenuate Ser20 site phosphorylation of p53 nor
p53  induction  mediated  by  treatment  with  X‐rays.  MOLT‐3  cells
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including hypoxia, glucose starvation, anoxia and 
perturbation of the AMP/ATP ratio, which could trigger 
p53 phosphorylation at Ser20. Of these signals, the most 
pronounced effect on Ser20 site phosphorylation was 
observed with the compound Acadesine (AICAR; 
Figure 6A; lane 2 vs 1), which is known to activate 
AMP-activated protein kinase (AMPK) by virtue of 
elevating the intracellular AMP levels. We had 
previously identified AMPK in a candidate kinase 
screen as an enzyme within the Calcium-Calmodulin 
kinase superfamily capable of targeting p53 at Ser20 in 
vitro [40]. The AICAR-mediated induction of Ser20 site 
phosphorylation was attenuated in a dose-dependent 
manner by the treatment of cells with the AMPK 
inhibitor Compound C (Figure 6A; lanes 6, 8, 10, 12 vs 
2). On the other hand, the AMPK inhibitor was unable 
to prevent Ser20 site phosphorylation induced by X-rays 
(Figure 6B; lanes 6, 8, 10, 12 vs 5, 7, 9, 11), indicating 
that AMPK is not the Ser20 site enzyme induced by X-
rays. Further, neither the CK1 inhibitor (Figure 6C), nor 
the ATM inhibitor (Figure 6D) abrogated the AICAR-
induced p53 Ser20 phosphorylation (Figure 6C & D; 
lanes 6, 8, 10, 12 vs 5, 7, 9, 11). These data therefore 
confirm that p53 Ser20 phosphorylation is ATM-
dependent after X-rays, CK1-dependent after virus 
infection, and AMPK-dependent after perturbation of 
AMP/ATP ratios (Figure 3). 
 
Together, these data form a paradigm demonstrating 
that (i) distinct stresses, including ionising radiation, 
virus infection and metabolic stress in the form of 
altered AMP/ATP ratios, can induce p53 phospho-
rylation at Ser20; a site that can stabilize p300 binding 
[21, 22, 32] and whose mutation promotes the 
development of spontaneous B-cell lymphoma in 
transgenic mice [37]; and (ii) the induction of this 
phosphorylation depends upon distinct signals and 





Phosphorylation in the Control of p53 Function 
 
A fundamental paradigm in p53 function is that p53 
“integrates” diverse stress signals towards a biological 
outcome. The integration mechanism is undefined but 
presumably involves both inhibition of p53’s 
degradation pathway and activation of its transcription 
function. p53 is controlled by a variety of post-
translational mechanisms (Figure 1). Of the many types 
of activating covalent modifications observed on p53, 
phosphorylation has been the most well-studied both 
biochemically and genetically. In this report, we have 
initiated a chemical biology screen to determine the 
mechanisms underlying the integration of stress signals 
to p53 activation. The fundamental question that we set 
out to answer is whether one common kinase pathway is 
able to target the Ser20 site within the transactivation 
domain of p53 in response to various stresses, or 
whether distinct kinases induced by different stresses 
are required to drive the same mechanism. We have 
focused on the Ser20 site since it is the most highly 
conserved phospho-acceptor site between urochordates 
and humans (Figure 2B) with well-documented genetic 
and biochemical effects. Phosphorylation at Ser20 has 
the most striking effect on stabilizing the p300:p53 
transcription complex through interactions with 
multiple LxxLL peptide binding domains on p300 [21, 
22]. Ser20 phospho-peptides or phospho-mimetic 
peptides can inhibit DNA-dependent acetylation of p53, 
showing an important role for this modification in 
driving p53 acetylation [32]. Mutation of the Ser20 site 
equivalent in mice to Ala20 gives rise to a spontaneous 
tumour phenotype in transgenic animals [37], which 
might, in part, explain its importance, as inferred from 
its high conservation throughout evolution. In this 
study, we show that phosphorylation at the Ser20 site of 
p53 increases in response to distinct stresses, including 
ionizing radiation, virus infection or metabolic stress, 
and we investigate the kinase signaling pathways 
involved in this phosphorylation using small molecule 
kinase inhibitors. 
 
The ATM Signal and Aging 
 
The phosphorylation of p53 at Ser20 after X-rays was 
not attributed to CHK1 or CHK2 despite original data 
supporting this model [38]. In addition, neither CK1 nor 
AMPK were the enzymes responsible for this 
modification. However, an ATM-dependent pathway 
does drive X-ray induced Ser20 site phosphorylation 
(Figure 3), highlighting an important clue to the 
identification of the X-ray-activated Ser20 site kinase. 
Transgenic mice with phospho-acceptor site mutations 
at the murine equivalent of the Ser15 ATM target site 
have been shown to exhibit an accelerated aging-
associated phenotype, along with an enhanced 
spontaneous development of late-onset lymphomas 
[48]. This indicates that the Ser15 phospho-acceptor site 
is important for the tumour suppression and anti-aging 
activity of p53, and implies that the kinases that mediate 
the phosphorylation of this site, such as ATM, 
contribute to both the tumour suppression and anti-
aging activities of p53 [48]. In a separate study, the p53 
response to several forms of stress was found to decline 
in various tissues of aging mice [49]. In addition, the 
expression and activity of the kinase ATM was shown 
to be decreased in older mice, again highlighting the 
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report also suggests that decreased p53 function could, at 




















































individuals. Finally, ATM is thought to be involved in 
telomere maintenance, and ATM-deficient cells undergo 
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We had originally initiated biochemical approaches to 
define the Ser20 kinase induced by DNA virus infection 
and demonstrated that this phosphorylation is mediated 
by CK1 (Figure 3) [46]. Although CK1 has not 
generated much interest in recent years due to the fact 
that it is not regulated by reversible phosphorylation as 
are many classic stress-activated enzymes, a recent 
study has shown that CK1 is the major enzyme that 
mediates TGF-β-dependent activation of p53, however, 
the site of phosphorylation is at Ser6/9 in the 
transactivation domain [51]. As CK1 is presumably 
regulated by interacting proteins, it is therefore of 
interest to understand how stresses as distinct as virus 
infection or TGF-β can organize the CK1 interactome to 
target two different sites on p53. CK1 has also been 
implicated in an aging-associated disease, namely 
Alzheimer’s disease. Indeed, the expression of CK1 has 
been shown to be up-regulated in the brain of 
Alzheimer patients [52, 53], and CK1 has been implica-
ted in the phosphorylation of the proteins tau and β-
secretase that have been linked to Alzheimer’s disease 
[54, 55]. More recently, CK1 has been shown to be 
involved in the formation of the neurotoxic peptide 
amyloid-β from amyloid precursor protein [56]. Given 
the role of the ARF-p53 pathway in aging (reviewed in 
[14]) and the likelihood that cytokines like TGF-β or 
interferons will play tissue-specific roles in p53 
modification, further examination of the role of CK1 in 
p53 aging models would be intriguing. 
 
The AMPK Signal and Aging 
 
One of the key changes that occur intracellularly after 
stress is ATP depletion and co-incident  elevation in the 
ratio of AMP/ATP. The enzyme AMPK senses this 
change and activates a signaling cascade to reprogram 
the cellular response to stress. It is interesting that 
AMPK is the enzyme that appears to target the Ser20 
site of p53 after artificially-induced changes in the 
AMP/ATP ratio using AICAR (Figure 3). In addition, 
this metabolic stress-induced Ser20 site phosphorylation 
is CK1- and ATM-independent, but is likely to be LKB-
dependent [57]. AMPK modulates several aging-
associated processes, such as mitochondrial biogenesis, 
obesity and decreased fatty acid oxidation, as well as 
insulin resistance (reviewed in [58]). In addition, 
AMPK activity has been shown to be decreased in 
aging rodent models [59, 60]. AMPK dysfunction could 
therefore be a key factor involved in the aging-
associated deficiencies in mitochondrial activity and 
metabolic regulation [58]. 
Do Kinases Modify the ARF-p53 Anti-aging Signal? 
 
Other cellular stresses, including aberrant oncogene 
activation and subsequent induction of ARF [61, 62] or 
extracellular signal-regulated kinases (ERKs) [63] and 
death-associated protein kinase 1 (DAPK-1; Figure 3) 
[64-66] have not been evaluated as of yet due to the 
lack of a common cell model that has an active ARF 
pathway. However, given the role of ARF-p53 axis in 
regulating longevity (reviewed in [14]), this signal will 
be important to evaluate. In fact, recent studies have 
shown that oncogene-induced senescence does not 
change p53 levels but increases its specific activity [67], 
a phenomenon that can be accomplished by p53 
phosphorylation at specific regulatory sites. 
 
Together, these data provide a paradigm explaining how 
distinct stresses can activate p53 (summarized in Figure 
3). In a biochemical approach to identify candidate 
kinases, we had previously identified many members of 
the calcium-calmodulin kinase superfamily, including 
CHK1/2, DAPK-1 and AMPK as p53 Ser20 site kinases 
[40]. The identification of CK1 as a major Ser20 site 
kinase was the first member outwith this superfamily 
that could target this site on p53 [46]. However, all 
these enzymes have a common biochemical requirement 
for a high affinity docking site in the core DNA-binding 
domain of p53 to catalyse Ser20 site phosphorylation in 
the transactivation domain [40, 46]. Thus, cells have 
evolved the ability to co-opt protein kinases that 
respond to distinct signals to dock to the same site in the 
p53 DNA-binding domain and induce Ser20 site 
phosphorylation. The fact that many of these enzymes 
including ATM, CK1 and AMPK can also modify 
pathways in cells linked to aging phenotypes highlights 
a future direction for investigation aimed at 
understanding how these kinase signaling pathways 




Chemicals, reagents and antibodies. All reagents were 
purchased from Sigma-Aldrich (Gillingham, UK), 
unless otherwise stated. The AMPK inhibitor 
Compound C (or Dorsomorphin), the CHK1 inhibitor 
SB218078, the CHK2 inhibitor, and the CK1 inhibitor 
D4476 were purchased from Merck Chemicals 
(Nottingham, UK). The ATM inhibitor KU-55933 was 
a gift from KuDOS Pharmaceuticals (Cambridge, UK). 
The DO-1 antibody to p53 was kindly provided by B. 
Vojtesek (Masaryk Memorial Cancer Institute, Brno, 
Czech Republic). P-p53 Ser20 antibody to p53 
phosphorylated at Ser20 was obtained from Santa Cruz  
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Biotechnology (supplied by Insight Biotechnology, 
Wembley, UK). Rabbit anti-mouse or swine anti-rabbit 
secondary antibodies were obtained from Dako (Ely, 
UK). 
 
Cell culture and treatments.  The human acute 
lymphoblastic leukaemia T-cell line, MOLT-3, was 
cultured in IMDM (Invitrogen, Paisley, UK) 
supplemented with 10% (v/v) foetal bovine serum 
(FBS; Autogen Bioclear, Calne, UK). MOLT-3 cells 
were infected with HHV-6B strain PL-1 as previously 
described [68]. Mock-infected and HHV-6B-infected 
MOLT-3 cells were treated with kinase inhibitors (or 
DMSO solvent controls) concomitantly with infection, 
for 48 hours. Alternatively, MOLT-3 cells were pre-
treated with kinase inhibitors (or DMSO solvent 
controls) for 44 hours before exposure (or sham 
exposure) to 6Gy X-ray using a cabinet X-ray machine 
(Faxitron X-Ray, Illinois, USA), and further culture for 
4 hours. Finally, MOLT-3 cells were pre-treated with 
kinase inhibitors (or DMSO solvent controls) for 24 
hours before treatment with 0.5mM Acadesine 
(AICAR), or a DMSO solvent control, and further 
culture for 24 hours. 
 
Cell lysis and Western blotting.  Cells were harvested 
and lysed in urea lysis buffer [7M urea, 20mM HEPES 
(pH 7.6), 25mM NaCl, 0.05% (v/v) Triton X-100, 0.1M 
dithiothreitol, 5mM NaF, 2mM Na3VO4, 2.5mM 
Na4P2O7, and 1 x Complete Mini Protease Inhibitor 
Cocktail (Roche Diagnostics, Burgess Hill, UK)] by 
incubation on ice for 30 minutes, followed by 
centrifugation at 13000g for 10 minutes at 4°C. Protein 
lysates (40μg) were resolved by SDS-polyacrylamide 
gel electrophoresis (PAGE) through 10% (w/v) tris-
glycine gels and transferred onto nitrocellulose 
membranes (Hybond ECL, GE Healthcare, Chalfont St 
Giles, UK). Membranes were probed with primary 
antibodies, followed by secondary antibodies 
conjugated to horse radish peroxidase (HRP). Bound 
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